ChristianaCare’s Helen F. Graham Cancer Center & Research Institute has become the first facility in Delaware to offer CARVYKTI, a chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or treatment-resistant multiple myeloma, a rare but serious form of blood cancer. “CAR-T cell therapy represents a paradigm shift in the treatment of multiple myeloma,” said Dr. Thomas Schwaab, Bank …